[
  {
    "ts": null,
    "headline": "Thermo Fisher Scientific Awarded $94.5 Million DoD Contract for US Navy Dosimetry Systems",
    "summary": "Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the best S&P 500 stocks with huge upside potential. On June 23, Thermo Fisher Scientific announced that it had been awarded a 5-year contract worth $94.5 million by the US Department of Defense (DoD). Under this contract, Thermo Fisher Scientific will supply the US Navy with a […]",
    "url": "https://finnhub.io/api/news?id=173543c2019381a6e8510a2d503873abfab995fa683fa0ce124a0fe4f7587427",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750884376,
      "headline": "Thermo Fisher Scientific Awarded $94.5 Million DoD Contract for US Navy Dosimetry Systems",
      "id": 135534473,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TMO",
      "source": "Yahoo",
      "summary": "Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the best S&P 500 stocks with huge upside potential. On June 23, Thermo Fisher Scientific announced that it had been awarded a 5-year contract worth $94.5 million by the US Department of Defense (DoD). Under this contract, Thermo Fisher Scientific will supply the US Navy with a […]",
      "url": "https://finnhub.io/api/news?id=173543c2019381a6e8510a2d503873abfab995fa683fa0ce124a0fe4f7587427"
    }
  },
  {
    "ts": null,
    "headline": "Solventum Removes Drinking-Water Unit From Thermo Fisher's Planned Filtration Buy",
    "summary": "Solventum Removes Drinking-Water Unit From Thermo Fisher's Planned Filtration Buy",
    "url": "https://finnhub.io/api/news?id=cfe3b4c3d0c65153b752f252b1cb08e949f1815676574355ec4c43655085a389",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750871040,
      "headline": "Solventum Removes Drinking-Water Unit From Thermo Fisher's Planned Filtration Buy",
      "id": 135541982,
      "image": "",
      "related": "TMO",
      "source": "MarketWatch",
      "summary": "Solventum Removes Drinking-Water Unit From Thermo Fisher's Planned Filtration Buy",
      "url": "https://finnhub.io/api/news?id=cfe3b4c3d0c65153b752f252b1cb08e949f1815676574355ec4c43655085a389"
    }
  },
  {
    "ts": null,
    "headline": "Thermo Fisher Scientific Inc. stock rises Wednesday, outperforms market",
    "summary": "Thermo Fisher Scientific Inc. stock rises Wednesday, outperforms market",
    "url": "https://finnhub.io/api/news?id=6d2e9cdf358b7bc6a33d7e11232cb4ee7c707d1b1924d845fce914e05e2a1aeb",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750869300,
      "headline": "Thermo Fisher Scientific Inc. stock rises Wednesday, outperforms market",
      "id": 135541983,
      "image": "",
      "related": "TMO",
      "source": "MarketWatch",
      "summary": "Thermo Fisher Scientific Inc. stock rises Wednesday, outperforms market",
      "url": "https://finnhub.io/api/news?id=6d2e9cdf358b7bc6a33d7e11232cb4ee7c707d1b1924d845fce914e05e2a1aeb"
    }
  },
  {
    "ts": null,
    "headline": "Oligonucleotide Synthesis Market Research and Global Forecast Report 2025-2030: Rising Emphasis on Advancing Drug Delivery and Scalable Synthesis Technologies for Oligonucleotide-Based Therapeutics",
    "summary": "The oligonucleotide synthesis market is forecasted to grow from USD 10.5 billion in 2025 to USD 24.7 billion by 2030 (CAGR of 18.6%). Key drivers include increasing demand for synthesized oligonucleotides for research and diagnostics, along with advancements in synthesis technology. By 2024, the oligonucleotide-based drugs segment is expected to dominate, driven by rising acceptance for treating rare diseases. North America leads the market due to established healthcare infrastructure and strong",
    "url": "https://finnhub.io/api/news?id=5933734a69830cc0d0d61813206e32f1c564b53a9e30255180dc0f7c77c7dafd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750862820,
      "headline": "Oligonucleotide Synthesis Market Research and Global Forecast Report 2025-2030: Rising Emphasis on Advancing Drug Delivery and Scalable Synthesis Technologies for Oligonucleotide-Based Therapeutics",
      "id": 135527220,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TMO",
      "source": "Yahoo",
      "summary": "The oligonucleotide synthesis market is forecasted to grow from USD 10.5 billion in 2025 to USD 24.7 billion by 2030 (CAGR of 18.6%). Key drivers include increasing demand for synthesized oligonucleotides for research and diagnostics, along with advancements in synthesis technology. By 2024, the oligonucleotide-based drugs segment is expected to dominate, driven by rising acceptance for treating rare diseases. North America leads the market due to established healthcare infrastructure and strong",
      "url": "https://finnhub.io/api/news?id=5933734a69830cc0d0d61813206e32f1c564b53a9e30255180dc0f7c77c7dafd"
    }
  },
  {
    "ts": null,
    "headline": "How Hologic Leverages Its Financial Firepower to Drive Long-Term Value",
    "summary": "Backed by robust profitability, HOLX deploys billions into acquisitions and repurchases to boost future earnings.",
    "url": "https://finnhub.io/api/news?id=cfe951dfb59117d6730ce2c6eb5e5504702ae03df04f9f0f15b3ceba41a24b21",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750857180,
      "headline": "How Hologic Leverages Its Financial Firepower to Drive Long-Term Value",
      "id": 135527221,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TMO",
      "source": "Yahoo",
      "summary": "Backed by robust profitability, HOLX deploys billions into acquisitions and repurchases to boost future earnings.",
      "url": "https://finnhub.io/api/news?id=cfe951dfb59117d6730ce2c6eb5e5504702ae03df04f9f0f15b3ceba41a24b21"
    }
  },
  {
    "ts": null,
    "headline": "Adial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements with Cambrex and Thermo Fisher Scientific for Drug Substance and Drug Product Supply",
    "summary": "Scope of Agreement with Cambrex to Provide Ondansetron HCL Drug Substance Under FDA Approved Drug Master File Scope Of Agreement With Thermo Fisher to Provide Manufacturing Services Including Demonstration, Clinical, Registration And Validation Batches of AD04 for US Clinical Trials And NDA Submission GLEN ALLEN, Va., June 25, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies",
    "url": "https://finnhub.io/api/news?id=37eda14f7d2ef8f2c46c2eaba1c9d2bde5c614da9aad22a42ebc0191f64830d2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750854600,
      "headline": "Adial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements with Cambrex and Thermo Fisher Scientific for Drug Substance and Drug Product Supply",
      "id": 135527222,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TMO",
      "source": "Yahoo",
      "summary": "Scope of Agreement with Cambrex to Provide Ondansetron HCL Drug Substance Under FDA Approved Drug Master File Scope Of Agreement With Thermo Fisher to Provide Manufacturing Services Including Demonstration, Clinical, Registration And Validation Batches of AD04 for US Clinical Trials And NDA Submission GLEN ALLEN, Va., June 25, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies",
      "url": "https://finnhub.io/api/news?id=37eda14f7d2ef8f2c46c2eaba1c9d2bde5c614da9aad22a42ebc0191f64830d2"
    }
  },
  {
    "ts": null,
    "headline": "Thermo Fisher, Ethris Partner to Offer Integrated mRNA Solutions for Biopharma",
    "summary": "Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the most active stocks to buy according to analysts. On June 13, Ethris announced a collaboration with Thermo Fisher Scientific. The partnership aims to provide a fully integrated messenger ribonucleic acid (mRNA) solution to biopharmaceutical developers globally. The core objective of the collaboration is to accelerate the […]",
    "url": "https://finnhub.io/api/news?id=741756090e9df0ad7b09fa429223378b6f4a089ca27d29fcb11988ee5bc8ee7e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750838975,
      "headline": "Thermo Fisher, Ethris Partner to Offer Integrated mRNA Solutions for Biopharma",
      "id": 135527223,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TMO",
      "source": "Yahoo",
      "summary": "Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the most active stocks to buy according to analysts. On June 13, Ethris announced a collaboration with Thermo Fisher Scientific. The partnership aims to provide a fully integrated messenger ribonucleic acid (mRNA) solution to biopharmaceutical developers globally. The core objective of the collaboration is to accelerate the […]",
      "url": "https://finnhub.io/api/news?id=741756090e9df0ad7b09fa429223378b6f4a089ca27d29fcb11988ee5bc8ee7e"
    }
  }
]